Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
- Study Title
- Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
- Teva Identifier
- C38072/3084
- ClinicalTrials.gov Identifier
- NCT01508936
- Study Status
- Completed
- Trial Condition(s)
- Eosinophilic Asthma
- Interventions
- Drug: Reslizumab | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 65 Years
- Trial Duration
- 02/01/2012 - 08/01/2013
- Phase
- Phase 3
